Clinical trial · Interventional
Augmented Sensory in Cancer-Related Neuropathic Patients"
Impact of Augmented Sensory Feedback on Motor Control and Risk of Falling in Cancer-Related Neuropathic Patients"
NCT07027215CI-TRIAL-00099420completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
this research studied the effect of augmented sensory feedback program on motor control and risk of falling in patient with CIPN.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Physical Therapy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gradual Intermittent pneumatic compression therapy (IPC),Balance excercises.PNF technique | Combination Product | — | UNRESOLVED |
| selected physical therapy program as arm excercises | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- control group 20 Patients"
- description
- Cancer-Related Neuropathic Patients"
- interventionNames
- Combination Product: selected physical therapy program as arm excercises
- type
- ACTIVE_COMPARATOR
- label
- study group 20 Patients"
- description
- Cancer-Related Neuropathic Patients"
- interventionNames
- Combination Product: Gradual Intermittent pneumatic compression therapy (IPC),Balance excercises.PNF technique
Primary outcomes (3)
- measure
- improvement of balance which was assessed by fall risk scale
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 35 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Forty female with age from 35-60 years * clinically diagnosed with CIPN after recovery from stage I or II breast cancer * The strength at the toes, ankles, knees, and hips, as determined by manual muscle tests, of at least 3/5. * The patients can walk independently with or without any assistive devices. Exclusion Criteria: * Patients with a history of hereditary peripheral neuropathy * Diseases that may contribute to peripheral nerve damage, such as diabetes or renal insufficiency, alcohol abuse, HIV, and vasculitis. * Patient who had central or peripheral neurologic disease, brain or spinal cord metastases * Orthopedic problems influencing gait, or foot ulcer at the moment of intake. * Patients with vestibular or neurological problems influencing gait parameters * Subjects who had participated in regular exercise, as defined as 150 min of light-to-moderate intensity exercise per week over the past year, were excluded from this trial.
References
Publications (3)
- RESULTSeretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014 Dec;155(12):2461-2470. doi: 10.1016/j.pain.2014.09.020. Epub 2014 Sep 23. PMID 25261162
- RESULTSchneberger S. "Prolife" perinatologist. N Engl J Med. 1992 Sep 10;327(11):812; author reply 813-4. No abstract available. PMID 1501662
- RESULTSienko KH, Seidler RD, Carender WJ, Goodworth AD, Whitney SL, Peterka RJ. Potential Mechanisms of Sensory Augmentation Systems on Human Balance Control. Front Neurol. 2018 Nov 12;9:944. doi: 10.3389/fneur.2018.00944. eCollection 2018. PMID 30483209